Profile data is unavailable for this security.
About the company
NIOX Group plc is a United Kingdom-based diagnostics and management company. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX VERO is also the device of choice by clinical research organizations for respiratory studies. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company provides products and services via its direct sales organization and extensive distributor network in over 50 countries.
- Revenue in GBP (TTM)46.00m
- Net income in GBP4.90m
- Incorporated2006
- Employees84.00
- LocationNiox Group PLCMagdalen Centre, 1 Robert Robinson AveOXFORD OX4 4GAUnited KingdomGBR
- Phone+44 186 540 5560
- Fax+44 186 578 4576
- Websitehttps://investors.niox.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enseval Putera Megatrading Tbk PT | 1.40bn | 32.95m | 270.81m | 5.08k | 8.22 | 0.8143 | 6.56 | 0.1935 | 279.85 | 279.85 | 11,888.59 | 2,824.64 | 2.74 | 7.42 | 6.71 | 6,386,735,000.00 | 6.44 | 7.53 | 9.91 | 10.81 | 10.07 | 10.47 | 2.35 | 2.80 | 1.46 | 38.64 | 0.0038 | 67.96 | 8.59 | 6.85 | 7.74 | 5.02 | -7.51 | 14.74 |
| Aarti Drugs Ltd | 202.92m | 16.30m | 276.99m | 1.28k | 17.09 | -- | 12.93 | 1.37 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Niox Group PLC | 46.00m | 4.90m | 280.85m | 84.00 | 58.74 | 4.36 | 30.86 | 6.11 | 0.0114 | 0.0122 | 0.1096 | 0.1542 | 0.5804 | 3.28 | 8.85 | 547,619.10 | 6.18 | 0.4655 | 6.66 | 0.5113 | 71.09 | 70.62 | 10.65 | 1.55 | 3.07 | -- | 0.0183 | 788.00 | 13.59 | 3.85 | -64.21 | -- | -37.28 | -- |
| Orchid Pharma Ltd | 66.09m | 4.21m | 283.65m | 737.00 | 67.42 | 2.77 | 40.52 | 4.29 | 10.31 | 10.31 | 162.05 | 251.16 | 0.4893 | 1.58 | 3.94 | 11,143,480.00 | 3.10 | 1.40 | 3.63 | 1.72 | 39.83 | 35.89 | 6.33 | 2.75 | 1.90 | 2.18 | 0.181 | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 95.21m | -38.99m | 288.29m | 2.10k | -- | 3.96 | -- | 3.03 | -0.9236 | -0.9236 | 2.26 | 1.72 | 0.3055 | 1.74 | 1.60 | 429,141.60 | -12.36 | 0.2178 | -22.13 | 0.3739 | 31.53 | 54.80 | -40.47 | 0.3213 | 0.5566 | -6.97 | 0.6414 | 700.10 | -21.26 | 1.60 | -2,629.23 | -- | 21.75 | -- |
| Clinuvel Pharmaceuticals Ltd | 49.21m | 18.73m | 288.60m | 16.00 | 15.47 | 2.31 | 14.92 | 5.86 | 0.7177 | 0.7177 | 1.89 | 4.80 | 0.3779 | 0.1857 | 3.54 | -- | 14.39 | 17.33 | 16.06 | 19.40 | 98.10 | 101.95 | 38.07 | 38.23 | 9.34 | -- | 0.0022 | 7.22 | -0.5085 | 23.46 | 1.50 | 19.17 | -19.60 | 14.87 |
| Eton Pharmaceuticals Inc | 51.35m | -4.88m | 290.05m | 31.00 | -- | 17.17 | -- | 5.65 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Harwood Capital LLPas of 21 May 2025 | 70.32m | 16.83% |
| Rathbones Investment Management Ltd.as of 07 Oct 2025 | 41.75m | 9.99% |
| Raymond James Wealth Management Ltd. (Investment Management)as of 25 Nov 2025 | 20.87m | 4.99% |
| Woodford Investment Management Ltd.as of 01 Nov 2025 | 15.26m | 3.65% |
| Artemis Investment Management LLPas of 20 Jan 2026 | 13.43m | 3.22% |
| Danske Bank A/S (Investment Management)as of 30 Sep 2025 | 12.48m | 2.99% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 01 Nov 2025 | 9.71m | 2.32% |
| Invesco Asset Management Ltd.as of 01 Apr 2025 | 9.04m | 2.16% |
| Brooks Macdonald Asset Management Ltd.as of 09 Apr 2025 | 8.84m | 2.12% |
| JPMorgan Asset Management (UK) Ltd.as of 11 Apr 2025 | 7.53m | 1.80% |
